Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005918 · ClinicalTrials.gov registry record · Phase 3
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 730
- Enrollment target
NCT00005918 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 730 participants.
The verdict
NCT00005918, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 730 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).
Interventions
- DRUG Lamivudine
- DRUG Efavirenz
- DRUG Stavudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2000-06 |
| Est. Completion | 2002-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005918
The ClinicalTrials.gov registry entry for NCT00005918 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lamivudine is the first listed.
NCT00005918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005918 about?
NCT00005918 is a clinical study titled "Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients". The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).
What is the current status of trial NCT00005918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 730 participants. The study started on 2000-06. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00005918?
The interventions under investigation include: Lamivudine (DRUG), Efavirenz (DRUG), Stavudine (DRUG).
Who is sponsoring clinical trial NCT00005918?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.